Stocks and Investing
Stocks and Investing
Mon, September 16, 2024
[ Mon, Sep 16th 2024
] - WOPRAI
[ Mon, Sep 16th 2024
] - WOPRAI
[ Mon, Sep 16th 2024
] - WOPRAI
[ Mon, Sep 16th 2024
] - WOPRAI
[ Mon, Sep 16th 2024
] - WOPRAI
[ Mon, Sep 16th 2024
] - WOPRAI
[ Mon, Sep 16th 2024
] - WOPRAI
[ Mon, Sep 16th 2024
] - WOPRAI
[ Mon, Sep 16th 2024
] - WOPRAI
[ Mon, Sep 16th 2024
] - WOPRAI
[ Mon, Sep 16th 2024
] - WOPRAI
[ Mon, Sep 16th 2024
] - WOPRAI
[ Mon, Sep 16th 2024
] - WOPRAI
[ Mon, Sep 16th 2024
] - WOPRAI
[ Mon, Sep 16th 2024
] - WOPRAI
[ Mon, Sep 16th 2024
] - WOPRAI
[ Mon, Sep 16th 2024
] - WOPRAI
[ Mon, Sep 16th 2024
] - WOPRAI
[ Mon, Sep 16th 2024
] - WOPRAI
[ Mon, Sep 16th 2024
] - WOPRAI
[ Mon, Sep 16th 2024
] - WOPRAI
[ Mon, Sep 16th 2024
] - WOPRAI
[ Mon, Sep 16th 2024
] - WOPRAI
[ Mon, Sep 16th 2024
] - WOPRAI
[ Mon, Sep 16th 2024
] - WOPRAI
[ Mon, Sep 16th 2024
] - WOPRAI
[ Mon, Sep 16th 2024
] - WOPRAI
[ Mon, Sep 16th 2024
] - WOPRAI
Emily Bodnar Reiterated (ACRV) at Strong Buy and Held Target at $22 on, Sep 16th, 2024
Emily Bodnar of HC Wainwright & Co., Reiterated "Acrivon Therapeutics, Inc." (ACRV) at Strong Buy and Held Target at $22 on, Sep 16th, 2024.
Emily, nor any peers, have made any analyst calls on ACRV in the last 4 months.
Warning: Undefined array key "user_peer_history" in /tmp/a6c06072cf4de09d3b84c924bfa9ab126ebc2b66_0.file.analysis.tpl.php on line 30
Contributing Sources